Sheba медициналық орталығы
| Израиль | Түркия | Австрия | |
| Химиотерапия | бастап $2,400 | бастап $2,430 | бастап $2,500 |
| Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау | бастап $135,000 | бастап $80,000 | бастап $180,000 |
| Туыстық донордан алынған сүйек кемігін аллогендік трансплантациялау | бастап $142,000 | бастап $65,000 | бастап $150,000 |
| Сүт безі рагында химиотерапия | бастап $22,500 | бастап $1,200 | бастап $15,000 |
| Сүйек кемігін трансплантациялау | бастап $75,000 | бастап $36,000 | бастап $140,000 |
Доктор Рам Рон Беркитт лимфомасын Израильдегі ең ірі әрі заманауи ауруханалардың бірі — Сураски (Ихилов) медициналық орталығында емдейді.
Бағаналы жасушаларды бірнеше жүз рет трансплантациялауды орындады — бұл агрессивті лимфомаларды емдеудің негізгі әдісі. Доктор Рам Ихилов ауруханасында жұмыс істейтін, үштік сертификаты бар гематолог-онколог болып табылады.
Дана Двек балалар ауруханасының балалар онкогематологиясы бөлімінің меңгерушісі — доктор Эль Хасид балалардағы сүйек кемігін және кіндік қанын трансплантациялауға маманданған.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Israeli hospitals confirm Burkitt lymphoma through a multi-step protocol involving tissue biopsy revisions, flow cytometry, and genetic testing. Specialized pathology departments identify the distinctive starry sky pattern and detect MYC gene translocations via Fluorescence In Situ Hybridization (FISH) to establish an immediate diagnosis.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center prioritize rapid diagnostics because Burkitt lymphoma can double in size within 24 hours. Their packages often include PET/CT and specialist consultations with headers like Dr. Amos Toren to ensure treatment starts within days of arrival. This speed is critical for outcomes in aggressive blood cancers.
Patient Consensus: Patients note it is important to bring original biopsy slides to avoid redundant surgical procedures. They often express relief at how quickly Israeli specialists move from initial consultation to the first treatment cycle.
Frontline protocols for Burkitt lymphoma in Israel prioritize intensive chemotherapy and advanced cellular therapies. Medical teams utilize rapid diagnostic staging with PET/CT and sentinel lymph node biopsies. JCI-accredited centers often incorporate bone marrow transplantation and CAR-T cell immunotherapy for high-risk or pediatric cases.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center leverage massive patient volumes of 2 million annually to refine transplant protocols. Our data shows pediatric BMT packages often include 30-day hospital stays. This matches the intensive recovery window required for successful engraftment in Burkitt lymphoma cases. Top specialists like Dr. Amos Toren provide integrated access to cell therapy and transplantation in one facility.
Patient Consensus: Patients note the relief of having complex diagnostic tests and specialized consultations bundled into the initial treatment phase. Many emphasize that having a multidisciplinary team immediately available helps manage the speed of this aggressive condition.
Treatment success rates for Burkitt's lymphoma in Israel generally range from 80% to 95% for complete remission. Pediatric long-term survival exceeds 90% using intensive chemotherapy. Adults and high-risk patients benefit from advanced CAR T-cell therapies and stem cell transplants at JCI-accredited facilities.
Bookimed Expert Insight: Israeli centers like Sheba Medical Center prioritize point-of-care CAR T-cell therapy for relapsed Burkitt's lymphoma. This onsite production significantly reduces waiting times for critically ill patients. Specialized hematologists like Dr. Abraham Avigdor often combine these high-tech immunotherapies with tailored bone marrow transplants. Our data shows pediatric packages for such advanced procedures cost around $160,000.
Patient Consensus: Patients note that doctors are exceptionally direct but deeply compassionate during high-intensity treatments. Many emphasize that having a multidisciplinary team available 24/7 provides crucial peace of mind during recovery.
Israeli hematologists manage central nervous system involvement using high-dose systemic chemotherapy and intrathecal delivery. These methods penetrate the blood-brain barrier to reach the spinal cord. Procedures include lumbar punctures for drug injection and advanced CAR T-cell therapy at JCI-accredited centers like Sheba Medical Center.
Bookimed Expert Insight: Patient volume impacts success in complex Burkitt cases. Sheba Medical Center treats over 2 million patients annually. Their experience enables precision delivery of CAR-T immunotherapies. Dr. Abraham Avigdor leads these protocols with 35+ years of clinical expertise. High-volume centers often offer more stable outcomes for aggressive lymphoma subtypes.
Patient Consensus: Patients note that multiple lumbar punctures are routine. They recommend documenting cognitive baseline before high-dose treatments to track memory changes. The medical staff makes pediatric care painless to avoid trauma.
Israel offers advanced hematological interventions for relapsed or refractory Burkitt lymphoma. These include in-house CAR T-cell therapy, targeted biologics, and bone marrow transplantation. Leading centers use molecular profiling to select salvage chemotherapy or enrollment in international clinical trials for resistant cases.
Bookimed Expert Insight: Israeli centers like Sheba Medical Center are pioneers in point-of-care CAR T-cell therapy. This allows doctors to manufacture cells on-site rather than shipping them to the US. This bypasses logistical delays and is critical for aggressive cancers like Burkitt lymphoma. Professor Amos Toren and his team specialize in integrating these cellular therapies with pediatric transplants. Their experience from over 2 million annual patient visits translates into highly refined protocols for high-risk relapses.
Patient Consensus: Patients note that Israeli doctors prioritize pain management and psychological comfort while acting with extreme urgency. Many emphasize the importance of getting pathology reviewed by local experts to confirm the Burkitt subtype before starting salvage protocols.
Sheba Medical Center and Sourasky Medical Center are the premier Israeli facilities for Burkitt lymphoma treatment. Both centers are JCI-accredited and ranked within the Newsweek World’s Best Hospitals. They offer advanced CAR-T immunotherapy and bone marrow transplantation under the care of internationally recognized hematologists.
Bookimed Expert Insight: While Sheba is a global top-10 hospital, Sourasky is among the top 10 most requested for medical tourism. Selecting Sheba often provides access to 30-day all-inclusive BMT packages. These bundles cover airport-clinic transfers and full board, which is essential for managing Burkitt lymphoma's intense therapy cycle.
Patient Consensus: Patients emphasize that the medical staff focuses on gentle care for children to avoid emotional trauma. Families note that teams explain every step of the process clearly during the high-speed treatment required for this condition.